2
RUDN University Immunologist offered a variant of the vaccine for allergies to Parietaria judaica

RUDN University Immunologist offered a variant of the vaccine for allergies to Parietaria judaica

RUDN University immunologist suggested which recombinant allergen molecules of the pollen of the postennitsa Parietaria Judaica are needed for allergen-specific immunotherapy of allergies.

On the territory of the Mediterranean countries, Eastern Europe, Australia, the postennitsa Judaica plant is widely distributed, which has a long flowering period. Its pollen causes allergies. To get rid of it, patients need allergen-specific immunotherapy. But to create vaccines, you need to identify the most clinically significant allergen molecules that are similar to the main epitopes (parts of the allergenic macromolecule), which are recognized by the immune system as natural sources of allergies.

Professor Roman Hanferyan and colleagues found that the vaccine against postennitsa Allergy should include two main allergens of the plant-proteins Par j 1 and Par j 2. Previously published studies have stated that only Par j 1 is sufficient in vaccines.

Roman Hanferyan and his colleagues obtained artificially created genetically engineered proteins Par j 1 and Par j 2 using recombinant DNA transfection in insect cells. These proteins were more similar to natural Par j 1 and Par j 2 from Parietaria pollen extract in their physical and chemical properties than previously studied recombinant proteins synthesized by yeast cells.

“Insects are the only object (unlike eukaryotic cells, microbes, and yeast) that uses so-called baculovirus expression systems, which provide a high level of protein expression with simple glycosylation and posttranslational modifications, ease of scaling, and simplified cell growth. Due to the similarity of systems of posttranslational modifications of eukaryotes, the synthesized protein will be close (or identical) to the native form of the protein we need,” the immunologist explained.

Biochemists have investigated the ability of Par j 1 and Par j 2 to cross-interact with immunoglobulin E to understand whether one of the two proteins can replace the other. Immunoglobulins E are the main class of antibodies responsible for the development of hypersensitivity reactions. Analysis of experiments showed that immunoglobulins E in blood serum after its preliminary incubation with one of the proteins interact with the second added protein. The researchers concluded that although the allergens Par j 1 and Par j 2 are similar, they do not replace each other, and the Parietaria pollen Allergy vaccine should include both of these proteins.

Biochemists have tested how fully the resulting protein molecules reflect the diversity of epitopes of allergens Parietaria. To do this, artificial allergens Par j 1 and Par j 2 were mixed with blood serum samples of patients with allergies and after their interaction, the amount of residual immunoglobulins E was measured, bound to the added natural pollen extract. A mixture of par j 1 and Par j 2 proteins almost completely prevented the binding of immunoglobulin E and Parietaria pollen extract. Professor Hunterian concluded that these two proteins correspond to the natural epitope spectrum of allergenic molecules of pollens.

Basophil activation tests in vitro confirmed the ability of recombinant proteins Par j 1 and Par j 2 to cause allergies, therefore, it can be expected that in vivo they will also show allergenic activity.

Currently, there are already effective vaccines based on artificially obtained allergens for the treatment of hypersensitivity to pollen of birch and grasses, but there are no such vaccines for postennitsa. The joint discovery of Hanferyan and his colleagues from Russia, Austria, Italy and Spain was the beginning of research on a new vaccine, but the timing of its production has not yet been determined. Preclinical research is ahead.

Article in the journal Scientific Reports.

Main Publications View all
15 Nov 2017
RUDN University scientists publish results of their scientific researches in highly-recognized in whole world and indexed in international databases journals (Web of Science, Scopus ect.). That, of course, corresponds to the high status of the University and its international recognition. Publications of June-September 2017 ( In Journals of categories Q1-Q3)
808
Scientific Conferences View all
03 Nov 2017
RUDN University organized the first 5G Summit R&D Russia on June 19 - 20, 2017
915
Similar newsletter View all
30 Dec
Biologists from RUDN University discovered the secret of flaxseed oil with long shelf life

Biologists from RUDN University working together with their colleagues from the Institute of Molecular Biology of the Russian Academy of Sciences and the Institute of Flax studied the genes that determine the fatty acid composition in flaxseed oil and identified polymorphisms in six of them. The team also found out what gene variations could extend the shelf life of flaxseed oil. This data can be used to improve the genetic selection of new flax breeds. The results were published in the BMC Plant Biology journal.

66
30 Dec 2020
Researchers conducted a systematic review of articles that analyzed the effect of medicine remedies used to treat COVID-19 during pregnancy.

RUDN physician Anna Borisova, in collaboration with colleagues from Italy, used effective searches and classified 123 articles on this research topic. A literature review was conducted by searching databases of medical and biological publications: PubMed, the U.S. National Library of Medicine, and Embase (Elsevier), a biomedical database.

59
30 Dec 2020
Each tree has a "cost". And smart technologies help to define it...

About Tree Talkers and soil structures, proper environmental management for sustainable urban development — in an interview with Elvira Davletyarov, Director of the Agrarian and Technological Institute of RUDN University.

56
Similar newsletter View all